- Home
- MEGL vs BIAF Comparison
MEGL vs BIAF Comparison
Compare MEGL & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MEGL | BIAF |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | Hong Kong | United States |
| Employees | N/A | 57 |
| Industry | Finance: Consumer Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1M | 4.6M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | MEGL | BIAF |
|---|---|---|
| Price | $1.08 | $2.10 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.9K | ★ 476.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $20.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $0.16 |
| 52 Week High | $2.62 | $13.50 |
Technical Indicators
Market Signals| Indicator | MEGL | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 55.98 | 78.12 |
| Support Level | $0.88 | $1.23 |
| Resistance Level | $1.18 | $3.58 |
| Average True Range (ATR) | 0.07 | 0.17 |
| MACD | 0.03 | 0.07 |
| Stochastic Oscillator | 67.20 | 62.00 |
Price Performance
Historical ComparisonAbout MEGL Magic Empire Global Limited
Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The companys offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.